July 2019
Volume 60, Issue 9
Open Access
ARVO Annual Meeting Abstract  |   July 2019
Day Regimes of CONbercept on CytokinEs of PDR Patients Undergoing Vitrectomy Trial (CONCEPT):Effects of preoperativeintravitreal conbercept on cytokines in the vitreous with proliferative diabetic retinopathy
Author Affiliations & Notes
  • Qinghuai Liu
    Jiangsu Province Hosp, Nanjing, China
  • Ping Xie
    Jiangsu Province Hosp, Nanjing, China
  • Songtao Yuan
    Jiangsu Province Hosp, Nanjing, China
  • Zizhong Hu
    Jiangsu Province Hosp, Nanjing, China
  • Footnotes
    Commercial Relationships   Qinghuai Liu, None; Ping Xie, None; Songtao Yuan, None; Zizhong Hu, None
  • Footnotes
    Support  National Basic Research Program of China 2017YFA0104101
Investigative Ophthalmology & Visual Science July 2019, Vol.60, 5372. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Qinghuai Liu, Ping Xie, Songtao Yuan, Zizhong Hu; Day Regimes of CONbercept on CytokinEs of PDR Patients Undergoing Vitrectomy Trial (CONCEPT):Effects of preoperativeintravitreal conbercept on cytokines in the vitreous with proliferative diabetic retinopathy . Invest. Ophthalmol. Vis. Sci. 2019;60(9):5372.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : To investigate the impact of preoperative injection of intravitreal conbercept (IVC) on the levels of 52 cytokines in the vitreous of eyes with proliferative diabeticretinopathy (PDR).

Methods : This is a prospective, randomized, controlled study. A total of 87 patients with PDR were recruited to IVC-1 Day (n = 21), IVC-3 Day (n = 19), IVC-5 Day (n=23), and IVC-7 Day (n = 24), according to the day receiving IVC before vitrectomy. Twenty four PDR patients receiving no IVC treatment before vitrectomy were grouped as IVC-sham group. Besides, 20 eyes from 20 patients with macular hole (MH) or epiretinal membrane (ERM) served as the Control group. Vitreous samples were obtained at the time of vitrectomy from all eyes, and the concentration of 52 cytokines such as VEGF-A, VEGF-B, PIGF was measured using Cytokine-antibody array or ELISAs.

Results : Among the 52 cytokines, VEGF-A, VEGF-B, Angiopoietin-2, CXCL12, endostatin, FGF, IL-18, MIF, MMP-1, MMP-3, MMP-7, PDGF-DD, PLGF, IL-1β, IL-2, IL-4, IL-9, IL-12, IL-13, IL-17A, G-CSF, IFN-g, FGF, IP-10, MCP-1, MIP-1a, PDGF-bb, MIP-1b, RANTES,TNF-a, TGF-b1, and TGF-b2 were increased significantly in the IVC-sham group compared to the Control group. In the IVC group, the mean levels (IVC/sham) of MMP-1 (207.33/305.37, P = 0.04), TGF-b2 (477.61/661.2, P<0.01) and CTGF (28.12/2282.19, P<0.01) were significantly lower when compared with those in the IVC-sham group. No significant difference was observed in the levels of TGF-b2 and CTGF between the IVC group and the Control group (TGF-b2p=0.11, CTGF p=0.97). In the subgroup analysis among groups of IVC-1 Day, IVC-3 Day, IVC-5 Day, and IVC-7 Day, we detected no difference of the concentration of the vitreous cytokines.

Conclusions : Vitreous MMP-1, TGF-b2, and CTGF levels were up-regulated markedly in patients with PDR and decreased significantly after IVC treatment. No difference of the vitreous cytokine concentration was detected in patients receiving IVC on different day within one week prior to vitrectomy.

This abstract was presented at the 2019 ARVO Annual Meeting, held in Vancouver, Canada, April 28 - May 2, 2019.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×